At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 60 enrolled
Drug / intervention
Travoprost 0.004%+Timolol 0.5% ophthalmic solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessing the Efficacy and Tolerability of Changing to DUOTRAV® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Bimatoprost 0.03%/Timolol 0.5% Therapy (Fixed or Unfixed)
In Brief
A Phase 4 clinical trial evaluating Travoprost 0.004%+Timolol 0.5% ophthalmic solution for Open-Angle Glaucoma and 2 related conditions. Completed, enrolled 60 participants.
Detailed Summary
The purpose of this study was to assess the efficacy and tolerability of changing to DUOTRAV® from prior bimatoprost 0.03%/timolol 0.5% pharmacotherapy in subjects with open-angle glaucoma or ocular hypertension having uncontrolled intraocular pressure (IOP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2011
Enrollment StartAug 2011
Primary CompletionNov 2012
TodayJul 2026
First PostedApr 1, 2011
Enrollment StartAug 1, 2011
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.3 years ago
Interventions
Travoprost 0.004%+Timolol 0.5% ophthalmic solutiondrug
Fixed dose combination topical ocular agent preserved with polyquaternium-1 (POLYQUAD)